IMRX – immuneering corporation - class a (US:NASDAQ)
Stock Stats
News
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 [Yahoo! Finance]
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
Immuneering (NASDAQ:IMRX) was downgraded by analysts at Wall Street Zen<
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA [Yahoo! Finance]
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
Form 10-Q Immuneering Corp For: Sep 30
Form 8-K Immuneering Corp For: Nov 12
Form SCHEDULE 13G Immuneering Corp Filed by: Empery Asset Management, LP
Form SCHEDULE 13G Immuneering Corp Filed by: FMR LLC
Form 4 Immuneering Corp For: Oct 03 Filed by: Feinberg Peter
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.